Assignee
IMMUNICOM INC
US·5 granted patents·20 pending applications·0 citations·filing 2018–2024
Top patents by PatentIndex Score
25 records- 0185US2024034797A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2023·Application pending·0 cites
- 0276US2022288294A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2022·Application pending·0 cites
- 0376US2022249363A1Augmentation of personalized tumor specific adaptive immunity through extracorporeal removal of immune blocking factorsIMMUNICOM INC·Filed 2022·Application pending·0 cites
- 0475US11814430B2Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Granted Nov 14, 2023·0 cites·11 claims
- 0574US11458236B2Reduced leaching of a ligandIMMUNICOM INC·Filed 2021·Granted Oct 4, 2022·0 cites·20 claims
- 0674US2022054726A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 0774US2022041730A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 0874US2022041729A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 0974US2022054727A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1074US2022054725A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1174US2022041732A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1274US2022041731A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1373US2022265913A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2022·Application pending·0 cites
- 1473US2022040087A1Augmentation of personalized tumor specific adaptive immunity through extracorporeal removal of immune blocking factorsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1573US2022054728A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1673US2022040088A1Augmentation of personalized tumor specific adaptive immunity through extracorporeal removal of immune blocking factorsIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1772US2021198362A1Increasing responses to checkpoint inhibitors by extracorporeal apheresisIMMUNICOM INC·Filed 2021·Application pending·0 cites
- 1871US11224858B1Reduced leaching of a ligandIMMUNICOM INC·Filed 2021·Granted Jan 18, 2022·0 cites·10 claims
- 1970US11123467B2System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2020·Granted Sep 21, 2021·0 cites·14 claims
- 2069US2022126272A1Reduced leaching of a ligandIMMUNICOM INC·Filed 2022·Application pending·0 cites
- 2168US2021146029A1System and method for removal of immune inhibitors from biological fluidsIMMUNICOM INC·Filed 2019·Application pending·0 cites
- 2265US2018243208A1Augmentation of personalized tumor specific adaptive immunity through extracorporeal removal of immune blocking factorsIMMUNICOM INC·Filed 2018·Application pending·0 cites
- 2364US2023137154A1Reduced leaching of a ligandIMMUNICOM INC·Filed 2022·Application pending·0 cites
- 2463US2024252732A1Modified tnf as a capture ligandIMMUNICOM INC·Filed 2024·Application pending·0 cites
- 2561US11957825B2Modified TNF as a capture ligandIMMUNICOM INC·Filed 2022·Granted Apr 16, 2024·0 cites·21 claims
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →